Real-World Maintenance Phase Persistence on Ustekinumab and Adalimumab in Ulcerative Colitis
DOI: https://doi.org/10.2147/ppa.s446861
2024-04-10
Patient Preference and Adherence
Abstract:Maryia Zhdanava, 1 Sumesh Kachroo, 2 Aditi Shah, 1 Zhijie Ding, 2 Patrick Lefebvre, 1 Ruizhi Zhao, 2 Caroline Kerner, 2 Dominic Pilon 1 1 Analysis Group, Inc, Montréal, QC, Canada; 2 Janssen Scientific Affairs, LLC, Horsham, PA, USA Correspondence: Maryia Zhdanava, Analysis Group, Inc, 1190 avenue des Canadiens-de-Montréal, Suite 1500, Montréal, QC, H3B 0G7, Canada, Tel +1-514-394-4469, Fax +1-514-394-4461, Email Purpose: To describe real-world persistence in bio-naïve and bio-experienced adults with ulcerative colitis (UC) treated with ustekinumab, a recently approved anti-interleukin 12/23 antibody, or adalimumab, an anti-TNF biologic. Methods: This is a descriptive, retrospective cohort study. Patients initiating ustekinumab or adalimumab (index date, between 10/21/2019 and 08/13/2021) were selected from the Komodo Health comprehensive dataset and stratified into bio-naïve and bio-experienced subgroups based on biologic use 12 months pre-index date. Endpoints evaluated at 12-months after maintenance phase start using Kaplan–Meier analysis included 1) persistence; 2) persistence while being corticosteroid-free (< 14 consecutive days of corticosteroid supply after day 90 post-index); and, 3) persistence while on monotherapy (no immunomodulators/non-index biologics/advanced therapies). Results: Ustekinumab cohort included 778 patients (236 bio-naïve, 542 bio-experienced) and adalimumab cohort included 1693 patients (1517 bio-naive, 176 bio-experienced). At 12 months after maintenance phase start, 75.5% and 50.5% of bio-naïve patients persisted on ustekinumab and adalimumab and 72.3% and 56.9% of bio-experienced patients persisted on ustekinumab and adalimumab, respectively. Further, 55.1% and 38.2% of bio-naïve patients were persistent and corticosteroid-free with ustekinumab and adalimumab; 43.7% and 33.4% of bio-experienced patients were persistent and corticosteroid-free with ustekinumab and adalimumab, respectively. Moreover, 68.1% and 44.5% of bio-naïve patients were persistent and on monotherapy with ustekinumab and adalimumab; 61.6% and 47.9% of bio-experienced patients were persistent and on monotherapy with ustekinumab and adalimumab, respectively. Conclusion: At 12 months after maintenance phase start, patients with UC treated with ustekinumab had numerically higher persistence, including persistence while corticosteroid-free and persistence while on monotherapy, than patients treated with adalimumab. Keywords: biologics, inflammatory bowel disease, outcomes research Ulcerative colitis (UC) and Crohn's disease are the two major types of inflammatory bowel disease. Specifically, UC is characterized by chronic autoimmune-mediated inflammation of the colon and rectum. 1 In 2016, the prevalence of UC among adults in the United States (US) was estimated to be nearly 500,000 and is steadily increasing. 2,3 Although there is no known pharmacological cure for UC, current pharmacological treatments aim to achieve mucosal healing, induce and maintain corticosteroid-free remission, and prevent hospitalization and surgery. 4 First-line treatments for moderate-to-severe UC recommended by the American College of Gastroenterology (ACG) and the American Gastroenterological Association (AGA) guidelines include glucocorticoids and biologic agents (with or without immunomodulators). 4,5 Once remission is achieved, guidelines recommend maintaining remission with a biologic/advanced therapy agent, while tapering off corticosteroids if used in the initial phase of treatment. 4–6 Anti-TNF agents, including adalimumab (approved by the US Food and Drug Administration [FDA] for UC in September 2012), have revolutionized the management of UC in recent decades. The ACG clinical guidelines recommend treatment with anti-TNF agents to induce and maintain remission in patients with moderate-to-severe UC. 4 Despite the integral role of anti-TNF agents, 50% of patients with UC do not respond to anti-TNF treatment or lose response over time, 7 highlighting the need for alternative therapies to manage UC. The anti-interleukin 12/23 antibody ustekinumab was approved by the FDA in October 2019 based on evidence from the UNIFI clinical trial demonstrating that ustekinumab was more effective than placebo for inducing and maintaining remission in patients with moderate-to-severe UC who had failed conventional or biologic therapy. 8,9 In this trial, clinical remission was induced in 18.8% of patients within 16 weeks; among patients achieving remission, 43.8% sustained clinical remission at week 44 while receiving ustekinumab once every 8 weeks. 9 Ustekinumab has -Abstract Truncated-
medicine, general & internal